1. Allison MAK, Jones SE, McGuffey, P (1989) Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. J Clin Oncol 7: 75
2. Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, Ochoa, AC (1990) Increased local antitumor effects of interleukin-2 liposomes in mice with MCA 106 sarcoma pulmonary metastases. Cancer Res 50: 1853
3. Ballas ZK, Rasmussen W, Van Otegham JK (1987) Lymphokine-activated killer (LAK) cells: II. Delineation of distinct murine LAK-precursor sub-populations. J Immunol 138: 1647
4. Blankenstein T, Qin Z, Überla K, Müller W, Rosen H, Volk H-D, Diamantstein T (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J Exp Med 173: 1047
5. Blay J-Y, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T (1990) Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res 50: 2371